Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Qibei Jiedu Formula is a Traditional Chinese Medicine (TCM) herbal formulation developed by Feng Li at the National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences. It is intended for the prevention and management of acute radiation dermatitis (ARD) in breast cancer patients undergoing adjuvant radiotherapy. The formula is a complex botanical mixture consisting of *Lithospermum erythrorhizon*, *Tribulus terrestris*, *Fried Shenqu*, and *Licorice root*. Administered orally as a decoction, it aims to reduce the incidence of grade 2 or higher radiation dermatitis, alleviate symptoms like erythema and pain, and accelerate wound healing. Its mechanism of action involves the modulation of inflammatory cytokines and the skin microbiota to support skin regeneration and reduce radiation-induced damage.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Qibei Jiedu Formula.